Oxaliplatin - A 10-year trajectory

Shingo Kanaji; Eiji Oki; Hiroshi Saeki; Hiroyuki Kitao; Yoshihiko Maehara; Yoshihiro Kakeji

Oxaliplatin - A 10-year trajectory

Shingo Kanaji, Eiji Oki, Hiroshi Saeki, Hiroyuki Kitao, Yoshihiko Maehara, Yoshihiro Kakeji

研究成果: Contribution to journal › Review article › 査読

抄録

Oxaliplatin (Elplat^® iv infusion solution) is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.

本文言語	英語
ページ（範囲）	715-722
ページ数	8
ジャーナル	Japanese Journal of Cancer and Chemotherapy
巻	43
号	6
出版ステータス	出版済み - 6 2016

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

文献へのアクセス

フィンガープリント「Oxaliplatin - A 10-year trajectory」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

@article{c495134379b44a93b9d2d3938c047cfe,

title = "Oxaliplatin - A 10-year trajectory",

abstract = "Oxaliplatin (Elplat{\textregistered} iv infusion solution) is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.",

author = "Shingo Kanaji and Eiji Oki and Hiroshi Saeki and Hiroyuki Kitao and Yoshihiko Maehara and Yoshihiro Kakeji",

year = "2016",

month = jun,

language = "English",

volume = "43",

pages = "715--722",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "6",

}

TY - JOUR

T1 - Oxaliplatin - A 10-year trajectory

AU - Kanaji, Shingo

AU - Oki, Eiji

AU - Saeki, Hiroshi

AU - Kitao, Hiroyuki

AU - Maehara, Yoshihiko

AU - Kakeji, Yoshihiro

PY - 2016/6

Y1 - 2016/6

N2 - Oxaliplatin (Elplat® iv infusion solution) is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.

AB - Oxaliplatin (Elplat® iv infusion solution) is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.

UR - http://www.scopus.com/inward/record.url?scp=84985987306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985987306&partnerID=8YFLogxK

M3 - Review article

C2 - 27306807

AN - SCOPUS:84985987306

VL - 43

SP - 715

EP - 722

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 6

ER -